



Claire Cassedy <clairepcassedy@gmail.com>

Inquiry regarding 84 FR 28063 Doc 2019-12708 - Prospective Grant of Exclusive Patent License: Lutetium-177 Radiotherapeutics Against Somatostatin-Receptor Expressing Neuroendocrine Tumors

Claire Cassedy <claire.cassedy@keionline.org>

Wed, Jun 26, 2019 at 10:34 AM

To: "Shmilovich, Michael (NIH/NHLBI) [E]" <michael.shmilovich@nih.gov>

Dear Mr. Shmilovich,

Thank you very much for your prompt reply. I have one more question regarding this proposed license:

-In working towards executing this license, has the NIH sought advice from the Attorney General (as is required under [40 USC § 559](#)) to determine if the "disposal to a private interest would tend to create or maintain a situation inconsistent with antitrust law"?

I appreciate all your assistance on these inquiries.

-

Claire Cassedy
Knowledge Ecology International
1621 Connecticut Avenue NW
Suite 500
Washington, DC 20009
Tel.: 1.202.332.2670

On Tue, Jun 25, 2019 at 11:28 AM Shmilovich, Michael (NIH/NHLBI) [E] <michael.shmilovich@nih.gov> wrote:

Dear Claire –

1. At what stage of development are the inventions listed?

Pre-clinical, early stage.

2. Has the government funded any clinical trials relevant to these technologies?

No

3. If the government has provided funding, how much has been spent by the government on these trials?
Can you provide NCT numbers?

N/A

4. How many years of exclusivity have been offered in this agreement, and what will the royalty rate be?

Royalty rates and terms of the license have yet to be negotiated but are, in general, confidential.

5. Regarding the company to receive the licenses, Molecular Targeting Technologies, Inc. are any former NIH employees associated with the company?

I'm not aware of any

From: Claire Cassedy <claire.cassedy@keionline.org>

Sent: Monday, June 24, 2019 12:32

To: Shmilovich, Michael (NIH/NHLBI) [E] <michael.shmilovich@nih.gov>

Subject: Inquiry regarding 84 FR 28063 Doc 2019-12708 - Prospective Grant of Exclusive Patent License: Lutetium-177 Radiotherapeutics Against Somatostatin-Receptor Expressing Neuroendocrine Tumors

Dear Mr. Shmilovich,

I am writing in reference to the Federal Register notice (84 FR 28063 Doc 2019-12708) regarding, "Prospective Grant of Exclusive Patent License: Lutetium-177 Radiotherapeutics Against Somatostatin-Receptor Expressing Neuroendocrine Tumors," for which you are listed as the contact for inquiries. I was hoping you could provide me with some further information regarding the status of the technologies.

1. At what stage of development are the inventions listed?
2. Has the government funded any clinical trials relevant to these technologies?
3. If the government has provided funding, how much has been spent by the government on these trials?
Can you provide NCT numbers?
4. How many years of exclusivity have been offered in this agreement, and what will the royalty rate be?
5. Regarding the company to receive the licenses, Molecular Targeting Technologies, Inc. are any former NIH employees associated with the company?

Thank you in advance for your assistance in this matter.

Best Regards,
Claire Cassedy

--

Claire Cassedy

Knowledge Ecology International

1621 Connecticut Avenue NW

Suite 500

Washington, DC 20009

Tel.: 1.202.332.2670